<p>维京治疗公司（Viking Therapeutics, Inc.）（NASDAQ: VKTX）股价周五上涨了 1.2%。该公司股价最高达到 65.86 美元，最后交易价为 65.37 美元。在交易过程中，约有 251,694 股股票换手，较平均每日交易量 4,312,246 股下降了 94%。该股票此前收盘价为 64.61 美元。</p>
<p>获取维京治疗公司的最新动态：</p>
<h2>华尔街分析师观点</h2>
<ul>
<li>维京治疗公司准备好再次飙升了吗？</li>
</ul>
<p>VKTX 已成为多份研究报告的主题。Oppenheimer 重申了对维京治疗公司的 “表现优异” 评级，并在 9 月 25 日星期三的研究报告中发布了对该公司的目标股价为 138.00 美元。HC Wainwright 重申了对维京治疗公司的 “买入” 评级，并在 10 月 9 日星期三的研究报告中设定了 90.00 美元的目标股价。摩根士丹利重申了对维京治疗公司的 “超配” 评级，并在 9 月 12 日星期四的研究报告中发布了 105.00 美元的目标股价。StockNews.com 在一份研究报告中将维京治疗公司的评级提升至 “卖出”。最后，雷蒙德詹姆斯将维京治疗公司的目标股价从 116.00 美元提高到 118.00 美元，并在 7 月 25 日星期四的研究报告中给予该公司 “强烈买入” 评级。一位分析师对该股票进行了卖出评级，十位分析师给予该公司买入评级，一位分析师给予该公司强烈买入评级。根据 MarketBeat.com 的数据，维京治疗公司的平均评级为 “中等买入”，目标股价共识为 108.60 美元。</p>
<p>获取我们对 VKTX 的最新研究报告</p>
<h2>维京治疗公司股价表现</h2>
<ul>
<li>维京治疗公司度过了一个难忘的一年：是时候买入了吗？</li>
</ul>
<p>该股票的五十日简单移动平均线为 62.47 美元，其二百日简单移动平均线为 62.16 美元。该公司的市值为 71.9 亿美元，市盈率为-70.29，贝塔系数为 1.00。</p>
<p>维京治疗公司（NASDAQ: VKTX）上次公布季度财报是在 7 月 24 日星期三。这家生物技术公司报告了该季度每股收益（EPS）为-0.20 美元，超过了分析师预期的-0.26 美元，超额 0.06 美元。去年同期，该公司每股收益为-0.19 美元。分析师预计，维京治疗公司今年将实现每股-1 美元的亏损。</p>
<h2>内部人士押注</h2>
<ul>
<li>维京治疗公司：积极财报推动制药股飙升</li>
</ul>
<p>在其他维京治疗公司的消息中，首席执行官 Brian Lian 于 9 月 20 日星期五以每股 70.83 美元的均价出售了 216,130 股公司股票。这次交易总价值为 15,308,487.90 美元。交易完成后，首席执行官现在直接持有公司股票 2,304,927 股，价值 163,257,979.41 美元。这次交易导致他们的持股比例减少了 0.00%。该交易已在美国证券交易委员会的一份法律文件中披露，可通过此超链接查看。此外，董事 J Matthew Singleton 于 8 月 14 日星期三以每股 57.53 美元的均价出售了 20,786 股公司股票。这些股票的总价值为 1,195,818.58 美元。交易完成后，该董事现在持有公司股票 9,500 股，价值 546,535 美元。这代表他们对该股票的持股比例减少了 0.00%。该交易已在一份提交给美国证券交易委员会的文件中披露，可通过此链接查看。此外，首席执行官 Brian Lian 于 9 月 20 日星期五以每股 70.83 美元的均价出售了 216,130 股维京治疗公司股票。这些股票的总交易额为 15,308,487.90 美元。交易完成后，首席执行官现在持有公司股票 2,304,927 股，价值约 163,257,979.41 美元。这代表他们对该股票的持股比例减少了 0.00%。此次交易的披露信息可在此处找到。内部人士在过去 90 天内已经抛售了价值 33,810,813 美元的公司股票，占公司股份的 4.70%。</p>
<h2>对维京治疗公司的对冲基金看法</h2>
<p>对冲基金最近对该股票的持仓进行了调整。GAMMA Investing LLC 在第三季度将其对维京治疗公司的持股增加了 124.6%。GAMMA Investing LLC 现在拥有 438 股这家生物技术公司的股票，价值 28,000 美元，比上一季度增加了 243 股。Massmutual Trust Co. FSB ADV 在第三季度将其对维京治疗公司的持仓增加了 84.3%。Massmutual Trust Co. FSB ADV 现在拥有 553 股这家生物技术公司的股票，价值 35,000 美元，比上一季度增加了 253 股。9258 Wealth Management LLC 在第一季度将其对维京治疗公司的持仓增加了 2.9%。9258 Wealth Management LLC 现在拥有 12,379 股这家生物技术公司的股票，价值 1,015,000 美元，比上一季度增加了 351 股。洛杉矶资本管理有限责任公司在第二季度将其对维京治疗公司的持仓增加了 3.1%。洛杉矶资本管理有限责任公司现在拥有 12,278 股这家生物技术公司的股票，价值 651,000 美元，比上一季度增加了 372 股。最后，Crossmark Global Holdings Inc.在第二季度将其对维京治疗公司的持仓增加了 5.5%。Crossmark Global Holdings Inc.现在拥有 7,457 股这家生物技术公司的股票，价值 395,000 美元，比上一季度增加了 386 股。对冲基金和其他机构投资者拥有公司股份的 76.03%。</p>
<h2>关于维京治疗公司（获取免费报告）</h2>
<p>Viking 治疗（Viking Therapeutics, Inc）是一家临床阶段的生物制药公司，专注于开发治疗代谢和内分泌疾病的新型疗法。该公司的主力药物候选是 VK2809，一种口服可用的组织和受体亚型选择性激动剂，作用于甲状腺激素受体β（TRß），目前正在进行 IIb 期临床试验，用于治疗经活检确认的非酒精性脂肪肝病患者，以及 NAFLD。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们比 Viking 治疗更喜欢的股票</li>
<li>工业产品股票投资</li>
<li>调查揭示：2024 年美国最令人垂涎的企业</li>
<li>什么是 Euro STOXX 50 指数？</li>
<li>三大股票投资石油潜在反弹行情</li>
<li>最大股票跌幅 - 今日最大跌幅股</li>
<li>分析师看好 CrowdStrike 股票的增长，尽管 7 月有所挫折</li>
</ul>
<p>_这则即时新闻警报是由叙事科技和来自 MarketBeat 的金融数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前已经经过 MarketBeat 编辑团队的审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</p>
<p>→ 奇怪的黄金法律传播（来自 Stansberry Research）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDA0MQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDA0MQ"/></p>
<h2>您现在是否应该投资 1,000 美元购买 Viking 治疗股票？</h2>
<p>在您考虑投资 Viking 治疗之前，您可能想听听这个。</p>
<p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户现在购买的股票清单...而 Viking 治疗并不在其中。</p>
<p>尽管 Viking 治疗目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

Viking治疗

<p>维京治疗（NASDAQ:VKTX）股价上涨 1.2%，至 0.37 美元，交易量明显低于平均水平。分析师对该股的评级褒贬不一，Oppenheimer 和 HC Wainwright 分别维持 “表现优异” 和 “买入” 评级。该股市值为 19 亿美元，市盈率为-70.29。最近内部人士的减持包括首席执行官 Brian Lian 出售了 216,130 股股票。对冲基金也增加了对该公司的持股。分析师预计 VKTX 的共识目标价为 0.60 美元</p>

<p>Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) shares rose 1.2% on Friday . The company traded as high as $65.86 and last traded at $65.37. Approximately 251,694 shares changed hands during trading, a decline of 94% from the average daily volume of 4,312,246 shares. The stock had previously closed at $64.61.</p>
<div class="lb-trans"><p>维京治疗公司（Viking Therapeutics, Inc.）（NASDAQ: VKTX）股价周五上涨了 1.2%。该公司股价最高达到 65.86 美元，最后交易价为 65.37 美元。在交易过程中，约有 251,694 股股票换手，较平均每日交易量 4,312,246 股下降了 94%。该股票此前收盘价为 64.61 美元。</p>
</div><p>Get <strong>Viking Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取维京治疗公司的最新动态：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<ul>
<li>Is Viking Therapeutics Ready For Another Surge?</li>
</ul>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
<ul>
<li>维京治疗公司准备好再次飙升了吗？</li>
</ul>
</div><p>VKTX has been the topic of a number of research reports. Oppenheimer restated an &#34;outperform&#34; rating and issued a $138.00 price target on shares of Viking Therapeutics in a research note on Wednesday, September 25th. HC Wainwright restated a &#34;buy&#34; rating and set a $90.00 price target on shares of Viking Therapeutics in a research note on Wednesday, October 9th. Morgan Stanley reiterated an &#34;overweight&#34; rating and issued a $105.00 price objective on shares of Viking Therapeutics in a research note on Thursday, September 12th. StockNews.com upgraded Viking Therapeutics to a &#34;sell&#34; rating in a research report on Tuesday. Finally, Raymond James boosted their target price on shares of Viking Therapeutics from $116.00 to $118.00 and gave the company a &#34;strong-buy&#34; rating in a research note on Thursday, July 25th. One analyst has rated the stock with a sell rating, ten have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Viking Therapeutics has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $108.60.</p>
<div class="lb-trans"><p>VKTX 已成为多份研究报告的主题。Oppenheimer 重申了对维京治疗公司的 “表现优异” 评级，并在 9 月 25 日星期三的研究报告中发布了对该公司的目标股价为 138.00 美元。HC Wainwright 重申了对维京治疗公司的 “买入” 评级，并在 10 月 9 日星期三的研究报告中设定了 90.00 美元的目标股价。摩根士丹利重申了对维京治疗公司的 “超配” 评级，并在 9 月 12 日星期四的研究报告中发布了 105.00 美元的目标股价。StockNews.com 在一份研究报告中将维京治疗公司的评级提升至 “卖出”。最后，雷蒙德詹姆斯将维京治疗公司的目标股价从 116.00 美元提高到 118.00 美元，并在 7 月 25 日星期四的研究报告中给予该公司 “强烈买入” 评级。一位分析师对该股票进行了卖出评级，十位分析师给予该公司买入评级，一位分析师给予该公司强烈买入评级。根据 MarketBeat.com 的数据，维京治疗公司的平均评级为 “中等买入”，目标股价共识为 108.60 美元。</p>
</div><p><strong>Get Our Latest Research Report on VKTX</strong></p>
<div class="lb-trans"><p>获取我们对 VKTX 的最新研究报告</p>
</div><h2>Viking Therapeutics Price Performance</h2>
<ul>
<li>Viking Therapeutics Is Having a Year to Remember: Time to Buy?</li>
</ul>
<div class="lb-trans"><h2>维京治疗公司股价表现</h2>
<ul>
<li>维京治疗公司度过了一个难忘的一年：是时候买入了吗？</li>
</ul>
</div><p>The stock's fifty day simple moving average is $62.47 and its 200-day simple moving average is $62.16. The firm has a market cap of $7.19 billion, a PE ratio of -70.29 and a beta of 1.00.</p>
<div class="lb-trans"><p>该股票的五十日简单移动平均线为 62.47 美元，其二百日简单移动平均线为 62.16 美元。该公司的市值为 71.9 亿美元，市盈率为-70.29，贝塔系数为 1.00。</p>
</div><p>Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 24th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.26) by $0.06. During the same period last year, the company earned ($0.19) earnings per share. Analysts expect that Viking Therapeutics, Inc. will post -1 earnings per share for the current year.</p>
<div class="lb-trans"><p>维京治疗公司（NASDAQ: VKTX）上次公布季度财报是在 7 月 24 日星期三。这家生物技术公司报告了该季度每股收益（EPS）为-0.20 美元，超过了分析师预期的-0.26 美元，超额 0.06 美元。去年同期，该公司每股收益为-0.19 美元。分析师预计，维京治疗公司今年将实现每股-1 美元的亏损。</p>
</div><h2>Insiders Place Their Bets</h2>
<ul>
<li>Viking Therapeutics: Pharma Stock Soars on Positive Earnings</li>
</ul>
<div class="lb-trans"><h2>内部人士押注</h2>
<ul>
<li>维京治疗公司：积极财报推动制药股飙升</li>
</ul>
</div><p>In other Viking Therapeutics news, CEO Brian Lian sold 216,130 shares of the firm's stock in a transaction on Friday, September 20th. The stock was sold at an average price of $70.83, for a total value of $15,308,487.90. Following the completion of the sale, the chief executive officer now directly owns 2,304,927 shares of the company's stock, valued at $163,257,979.41. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. In other Viking Therapeutics news, Director J Matthew Singleton sold 20,786 shares of the company's stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $57.53, for a total value of $1,195,818.58. Following the transaction, the director now owns 9,500 shares of the company's stock, valued at $546,535. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Brian Lian sold 216,130 shares of Viking Therapeutics stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $70.83, for a total transaction of $15,308,487.90. Following the sale, the chief executive officer now owns 2,304,927 shares of the company's stock, valued at approximately $163,257,979.41. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 516,671 shares of company stock valued at $33,810,813 in the last ninety days. 4.70% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他维京治疗公司的消息中，首席执行官 Brian Lian 于 9 月 20 日星期五以每股 70.83 美元的均价出售了 216,130 股公司股票。这次交易总价值为 15,308,487.90 美元。交易完成后，首席执行官现在直接持有公司股票 2,304,927 股，价值 163,257,979.41 美元。这次交易导致他们的持股比例减少了 0.00%。该交易已在美国证券交易委员会的一份法律文件中披露，可通过此超链接查看。此外，董事 J Matthew Singleton 于 8 月 14 日星期三以每股 57.53 美元的均价出售了 20,786 股公司股票。这些股票的总价值为 1,195,818.58 美元。交易完成后，该董事现在持有公司股票 9,500 股，价值 546,535 美元。这代表他们对该股票的持股比例减少了 0.00%。该交易已在一份提交给美国证券交易委员会的文件中披露，可通过此链接查看。此外，首席执行官 Brian Lian 于 9 月 20 日星期五以每股 70.83 美元的均价出售了 216,130 股维京治疗公司股票。这些股票的总交易额为 15,308,487.90 美元。交易完成后，首席执行官现在持有公司股票 2,304,927 股，价值约 163,257,979.41 美元。这代表他们对该股票的持股比例减少了 0.00%。此次交易的披露信息可在此处找到。内部人士在过去 90 天内已经抛售了价值 33,810,813 美元的公司股票，占公司股份的 4.70%。</p>
</div><h2>Hedge Funds Weigh In On Viking Therapeutics</h2>
<div class="lb-trans"><h2>对维京治疗公司的对冲基金看法</h2>
</div><p>Hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC lifted its stake in Viking Therapeutics by 124.6% during the 3rd quarter. GAMMA Investing LLC now owns 438 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 243 shares in the last quarter. Massmutual Trust Co. FSB ADV lifted its position in shares of Viking Therapeutics by 84.3% during the third quarter. Massmutual Trust Co. FSB ADV now owns 553 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 253 shares in the last quarter. 9258 Wealth Management LLC boosted its stake in shares of Viking Therapeutics by 2.9% in the first quarter. 9258 Wealth Management LLC now owns 12,379 shares of the biotechnology company's stock valued at $1,015,000 after purchasing an additional 351 shares during the period. Los Angeles Capital Management LLC boosted its stake in shares of Viking Therapeutics by 3.1% in the second quarter. Los Angeles Capital Management LLC now owns 12,278 shares of the biotechnology company's stock valued at $651,000 after purchasing an additional 372 shares during the period. Finally, Crossmark Global Holdings Inc. grew its holdings in shares of Viking Therapeutics by 5.5% in the second quarter. Crossmark Global Holdings Inc. now owns 7,457 shares of the biotechnology company's stock valued at $395,000 after purchasing an additional 386 shares in the last quarter. Hedge funds and other institutional investors own 76.03% of the company's stock.</p>
<div class="lb-trans"><p>对冲基金最近对该股票的持仓进行了调整。GAMMA Investing LLC 在第三季度将其对维京治疗公司的持股增加了 124.6%。GAMMA Investing LLC 现在拥有 438 股这家生物技术公司的股票，价值 28,000 美元，比上一季度增加了 243 股。Massmutual Trust Co. FSB ADV 在第三季度将其对维京治疗公司的持仓增加了 84.3%。Massmutual Trust Co. FSB ADV 现在拥有 553 股这家生物技术公司的股票，价值 35,000 美元，比上一季度增加了 253 股。9258 Wealth Management LLC 在第一季度将其对维京治疗公司的持仓增加了 2.9%。9258 Wealth Management LLC 现在拥有 12,379 股这家生物技术公司的股票，价值 1,015,000 美元，比上一季度增加了 351 股。洛杉矶资本管理有限责任公司在第二季度将其对维京治疗公司的持仓增加了 3.1%。洛杉矶资本管理有限责任公司现在拥有 12,278 股这家生物技术公司的股票，价值 651,000 美元，比上一季度增加了 372 股。最后，Crossmark Global Holdings Inc.在第二季度将其对维京治疗公司的持仓增加了 5.5%。Crossmark Global Holdings Inc.现在拥有 7,457 股这家生物技术公司的股票，价值 395,000 美元，比上一季度增加了 386 股。对冲基金和其他机构投资者拥有公司股份的 76.03%。</p>
</div><h2>About Viking Therapeutics (Get Free Report)</h2>
<div class="lb-trans"><h2>关于维京治疗公司（获取免费报告）</h2>
</div><p>Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.</p>
<div class="lb-trans"><p>Viking 治疗（Viking Therapeutics, Inc）是一家临床阶段的生物制药公司，专注于开发治疗代谢和内分泌疾病的新型疗法。该公司的主力药物候选是 VK2809，一种口服可用的组织和受体亚型选择性激动剂，作用于甲状腺激素受体β（TRß），目前正在进行 IIb 期临床试验，用于治疗经活检确认的非酒精性脂肪肝病患者，以及 NAFLD。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than Viking Therapeutics</li>
<li>Industrial Products Stocks Investing</li>
<li>Survey Reveals: America’s Most Coveted Businesses in 2024</li>
<li>What is the Euro STOXX 50 Index?</li>
<li>Top 3 Stocks to Play Oil’s Potential Comeback Rally</li>
<li>Biggest Stock Losers - Today’s Biggest Percentage Decliners</li>
<li>Analysts See Growth in CrowdStrike Stock Despite July Setback</li>
</ul>
<div class="lb-trans"><h2>精选故事</h2>
<ul>
<li>五只我们比 Viking 治疗更喜欢的股票</li>
<li>工业产品股票投资</li>
<li>调查揭示：2024 年美国最令人垂涎的企业</li>
<li>什么是 Euro STOXX 50 指数？</li>
<li>三大股票投资石油潜在反弹行情</li>
<li>最大股票跌幅 - 今日最大跌幅股</li>
<li>分析师看好 CrowdStrike 股票的增长，尽管 7 月有所挫折</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p>_这则即时新闻警报是由叙事科技和来自 MarketBeat 的金融数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前已经经过 MarketBeat 编辑团队的审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</p>
</div><p>→ Strange gold laws spreading (From Stansberry Research)(Ad)</p>
<div class="lb-trans"><p>→ 奇怪的黄金法律传播（来自 Stansberry Research）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDA0MQ" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=10041&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Viking Therapeutics right now?</h2>
<div class="lb-trans"><h2>您现在是否应该投资 1,000 美元购买 Viking 治疗股票？</h2>
</div><p>Before you consider Viking Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑投资 Viking 治疗之前，您可能想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户现在购买的股票清单...而 Viking 治疗并不在其中。</p>
</div><p>While Viking Therapeutics currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Viking 治疗目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Viking 治疗（NASDAQ:VKTX）股价上涨 1.2% - 事情经过如下